What does localisation deliver in public procurement?

Locally manufactured products receive preferences, which affects access to the hospital procurement channel. For products with a high hospital share this is often decisive.

Is localisation linked to the 2027 GMP requirement?

Yes. From 1 January 2027 GMP compliance becomes mandatory, and moving production to a certified site is one way to retain market presence.

Can products be supplied from Uzbekistan to other CIS countries?

The site can serve as a base for regional supply, but specific opportunities depend on each country's regulatory requirements.

How does a localisation project start?

With a feasibility assessment: review of the dosage form, composition, equipment requirements and raw material availability.

Which dosage forms can be produced?

Ampoules (2, 5, 10 ml), tablets, capsules and blister packaging. A building for suppositories, syrups and ointments is under construction.

Manufacturing

Localising production in Uzbekistan: what it delivers to a foreign manufacturer

Name: Localising production
Creator: Laxisam Pharmaceuticals
Published: 2026-08-30

обновлено 30 августа 2026 · 3 мин чтения · Laxisam Pharmaceuticals

Localisation decisions are usually reduced to a cost comparison. In Uzbekistan three further factors are at work: preferences for local products in government procurement, mandatory GMP from 2027, and logistics. Here is each of them.

Factor 1. Government procurement

Public procurement is a significant sales channel for a number of therapeutic groups. Locally manufactured products receive preferences in it, so localisation changes not only unit cost but access to the channel itself. For hospital-oriented products this is often the decisive argument.

Factor 2. The regulatory deadline

From 1 January 2027 GMP compliance becomes mandatory under Decree UP-137. For companies whose sites lack such confirmation, localising at a certified facility is a way to retain market presence. Certified capacity, however, is limited.

Factor 3. Economics

No inbound logistics for finished products and none of the associated risks.
Shorter lead times to the domestic market and less currency exposure along the chain.
More flexible batch sizing against actual demand.
Local packaging and labelling without additional shipping.

Factor 4. Regional market access

A site in Uzbekistan can serve as a base for supplies to CIS countries. The specific opportunities depend on each country's regulatory requirements and are assessed separately.

What to evaluate before deciding

Market size for the product in Uzbekistan and the share of the hospital segment.
Compatibility of the dosage form with the site's equipment.
Regulatory route: new registration, recognition or variation.
Availability of raw and packaging materials, including alternative suppliers.
Timelines: technology transfer plus regulatory procedures.
Minimum economically viable batch size.

About the site

Laxisam Pharmaceuticals has operated in Tashkent since 2011. Production area — 11,800 m² on a 0.67 ha plot. National GMP certificate No. GMP-08:2024, licence No. 15998. Capacity: ampoules up to 24,000 per hour (2, 5 and 10 ml), tablets 80,000 per hour, capsules 50,000 per hour, 14.8 million blister packs per year. A 6,750 m² building for suppositories, syrups and ointments is under construction.

Frequently asked questions

What does localisation deliver in public procurement?: Locally manufactured products receive preferences, which affects access to the hospital procurement channel. For products with a high hospital share this is often decisive.
Is localisation linked to the 2027 GMP requirement?: Yes. From 1 January 2027 GMP compliance becomes mandatory, and moving production to a certified site is one way to retain market presence.
Can products be supplied from Uzbekistan to other CIS countries?: The site can serve as a base for regional supply, but specific opportunities depend on each country's regulatory requirements.
How does a localisation project start?: With a feasibility assessment: review of the dosage form, composition, equipment requirements and raw material availability.
Which dosage forms can be produced?: Ampoules (2, 5, 10 ml), tablets, capsules and blister packaging. A building for suppositories, syrups and ointments is under construction.